Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN)
CUSIP: 29337E102
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 58,923,077
- Total 13F shares
- 59,434,902
- Share change
- +9,547,046
- Total reported value
- $1,192,251,085
- Price per share
- $20.06
- Number of holders
- 123
- Value change
- +$192,194,924
- Number of buys
- 79
- Number of sells
- 43
Quarterly Holders Quick Answers
What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29337E102:
Top shareholders of ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
3/4/5
13D/G
13F
|
Director, 10%+ Owner · Company |
13%
from 13D/G
|
7,663,349
|
$169,666,547 | — | 16 May 2024 | |
| Commodore Capital LP |
13D/G
3/4/5
13F
|
10%+ Owner · Company |
9.9%
|
6,022,957
|
$135,215,385 | $0 | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
11%
|
6,609,529
|
$130,075,531 | — | 31 Mar 2025 | |
| Fairmount Funds Management LLC |
13D/G
13F
|
Company |
6.3%
|
3,711,444
|
$83,321,918 | +$11,419,103 | 30 Jun 2025 | |
| VR Adviser, LLC |
13F
|
Company |
6.8%
|
4,026,331
|
$79,238,194 | — | 31 Mar 2025 | |
| David P. Bonita |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
4,207,568
mixed-class rows
|
$63,552,894 | — | 02 Jun 2022 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
5.1%
|
2,941,395
|
$59,005,266 | $0 | 30 Jun 2025 | |
| 5AM Partners VI, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,835,975
|
$57,156,028 | — | 14 Feb 2024 | |
| Polar Capital Holdings Plc |
13D/G
13F
|
Company |
5.2%
|
2,536,881
|
$56,952,978 | +$3,304,932 | 30 Jun 2025 | |
| New Enterprise Associates 14, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,611,050
|
$39,518,242 | — | 05 Apr 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.3%
|
1,972,239
|
$38,813,664 | — | 31 Mar 2025 | |
| Mark Chin |
3/4/5
|
Director |
—
mixed-class rows
|
2,352,572
mixed-class rows
|
$35,477,530 | — | 02 Jun 2022 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.7%
|
1,570,503
|
$33,051,236 | — | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
3/4/5
13F
|
Former 10% owner · Company |
1.4%
from 13F
|
2,122,465
|
$32,123,508 | — | 23 Feb 2023 | |
| Braden M. Leonard |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,997,774
|
$30,236,309 | — | 03 Jan 2023 | |
| 5AM Venture Management, LLC |
13F
|
Company |
2.2%
|
1,322,477
|
$26,026,347 | — | 31 Mar 2025 | |
| Barbara Dalton |
3/4/5
|
Director |
—
mixed-class rows
|
1,566,222
mixed-class rows
|
$23,576,122 | — | 02 Jun 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.9%
|
1,123,138
|
$22,103,356 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.6%
|
967,502
|
$19,040,439 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
819,173
|
$16,124,823 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
805,157
|
$15,845,490 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.3%
|
780,902
|
$15,368,151 | — | 31 Mar 2025 | |
| Blackstone Inc. |
13F
|
Company |
1.3%
|
762,307
|
$15,002,202 | — | 31 Mar 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.1%
|
671,358
|
$13,212,325 | — | 31 Mar 2025 | |
| Carl Goldfischer |
3/4/5
|
Director |
—
mixed-class rows
|
711,880
mixed-class rows
|
$10,645,656 | — | 02 Jun 2022 | |
| First Turn Management, LLC |
13F
|
Company |
0.91%
|
535,092
|
$10,530,611 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.79%
|
465,871
|
$9,168,341 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.76%
|
450,000
|
$8,856,000 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.57%
|
338,650
|
$6,664,633 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.49%
|
289,538
|
$5,698,108 | — | 31 Mar 2025 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.45%
|
265,269
|
$5,220,494 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.44%
|
259,537
|
$5,107,688 | — | 31 Mar 2025 | |
| Patient Square Capital LP |
13F
|
Company |
0.43%
|
253,838
|
$4,995,532 | — | 31 Mar 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.42%
|
250,000
|
$4,920,000 | — | 31 Mar 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.41%
|
240,000
|
$4,723,200 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.36%
|
211,752
|
$4,167,279 | — | 31 Mar 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.33%
|
197,279
|
$3,882,000 | — | 31 Mar 2025 | |
| David M. Mott |
3/4/5
|
Director |
—
mixed-class rows
|
237,724
mixed-class rows
|
$3,469,305 | — | 02 Jun 2022 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.29%
|
169,774
|
$3,341,152 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.24%
|
139,918
|
$2,753,589 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.23%
|
132,887
|
$2,615,216 | — | 31 Mar 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.2%
|
120,430
|
$2,370,062 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.19%
|
114,833
|
$2,259,913 | — | 31 Mar 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.19%
|
112,459
|
$2,213,193 | — | 31 Mar 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.19%
|
111,743
|
$2,199,102 | — | 31 Mar 2025 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.18%
|
105,542
|
$2,077,065 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.18%
|
104,099
|
$2,048,668 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.16%
|
93,567
|
$1,841,399 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.14%
|
84,700
|
$1,666,896 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.14%
|
81,315
|
$1,600,280 | — | 31 Mar 2025 |
Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) as of Q2 2025
As of 30 Jun 2025,
Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) was held by
123 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,434,902 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, FMR LLC, Commodore Capital LP, VR ADVISER, LLC, Fairmount Funds Management LLC, Polar Capital Holdings Plc, BlackRock, Inc., VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, and CITADEL ADVISORS LLC.
This page lists
123
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
118
Q2 2025 holders
123
Holder diff
5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.